Tizanidine Tablet
Product Images NDC 43063-868

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 43063-868). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (43063868)

Label for Tizanidine USP 2 mg tablets by PD-Rx Pharmaceuticals, Inc. The label shows the product name, strength, and quantity of 30 tablets. It includes the NDC 43063-868-30, lot number D22B12, and expiration date 07/2023. The label contains warnings about drowsiness and interchangeability with capsules, along with dosage and storage instructions.*

FDA Label Image

Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 01

Chemical structure of the active ingredient tizanidine. The structure includes a chloro-substituted aromatic ring fused to a thiazole ring, with additional nitrogen atoms and a hydrochloride (HCl) notation indicating the salt form.*

FDA Label Image

Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 02

A line graph showing plasma tizanidine concentration (ng/mL) over time (hours from dosing) comparing four conditions: 4 mg tizanidine tablets with and without food, and 4 mg tizanidine capsules with and without food. The graph illustrates concentration peaks within the first few hours post dosing, followed by a decline towards zero by 24 hours.*

FDA Label Image

Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 03

Line graph showing improvement in Ashworth Score over 6 hours post-dose comparing 16 mg and 8 mg doses of tizanidine with placebo. The graph illustrates higher improvement scores for both tizanidine doses relative to placebo, with peak improvements around 2 hours post-dose.*

FDA Label Image

Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 04

A graphical plot showing improvement in Ashworth Score over time points including End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). The chart compares Tizanidine (mean dose 28.8 mg) versus placebo, with improvement scores on the vertical axis indicating greater improvement as values decrease.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.